FR3044017B1 - Procede de transfection transitoire pour la production retrovirale - Google Patents

Procede de transfection transitoire pour la production retrovirale Download PDF

Info

Publication number
FR3044017B1
FR3044017B1 FR1661254A FR1661254A FR3044017B1 FR 3044017 B1 FR3044017 B1 FR 3044017B1 FR 1661254 A FR1661254 A FR 1661254A FR 1661254 A FR1661254 A FR 1661254A FR 3044017 B1 FR3044017 B1 FR 3044017B1
Authority
FR
France
Prior art keywords
transient transfection
transfection method
bacs
retroviral production
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1661254A
Other languages
English (en)
French (fr)
Other versions
FR3044017A1 (fr
Inventor
Sabine Johnson
Celeste PALLANT
Eirini Vamva
Conrad Vink
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1520764.0A external-priority patent/GB201520764D0/en
Priority claimed from GBGB1609354.4A external-priority patent/GB201609354D0/en
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Publication of FR3044017A1 publication Critical patent/FR3044017A1/fr
Application granted granted Critical
Publication of FR3044017B1 publication Critical patent/FR3044017B1/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/89—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection
    • C12N15/895—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microinjection using biolistic methods
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16051—Methods of production or purification of viral material
    • C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/50—Vectors for producing vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FR1661254A 2015-11-24 2016-11-21 Procede de transfection transitoire pour la production retrovirale Expired - Fee Related FR3044017B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB15207640 2015-11-24
GBGB1520764.0A GB201520764D0 (en) 2015-11-24 2015-11-24 Transient transfection method for retroviral production
GBGB1609354.4A GB201609354D0 (en) 2016-05-26 2016-05-26 Transient transfection method for retroviral production
GB16093544 2016-05-26

Publications (2)

Publication Number Publication Date
FR3044017A1 FR3044017A1 (fr) 2017-05-26
FR3044017B1 true FR3044017B1 (fr) 2019-05-03

Family

ID=57348703

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1661254A Expired - Fee Related FR3044017B1 (fr) 2015-11-24 2016-11-21 Procede de transfection transitoire pour la production retrovirale

Country Status (15)

Country Link
US (2) US10450574B2 (OSRAM)
EP (1) EP3380605A1 (OSRAM)
JP (1) JP7110096B2 (OSRAM)
KR (1) KR102067352B1 (OSRAM)
CN (1) CN108291211A (OSRAM)
AU (1) AU2016359838B2 (OSRAM)
BR (1) BR112018010639A2 (OSRAM)
CA (1) CA3006285A1 (OSRAM)
DE (1) DE102016122317A1 (OSRAM)
FR (1) FR3044017B1 (OSRAM)
IL (1) IL259223B (OSRAM)
IT (1) IT201600117287A1 (OSRAM)
RU (1) RU2749717C2 (OSRAM)
SA (1) SA518391585B1 (OSRAM)
WO (1) WO2017089307A1 (OSRAM)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3294756T3 (da) * 2015-05-15 2021-02-22 Flash Therapeutics Retroviral partikel, omfattende mindst to forskellige indkapslede, ikke-virale RNA'er
BR112018010635A2 (pt) * 2015-11-24 2018-11-27 Glaxosmithkline Ip Dev Ltd linhagens celulares estáveis para a produção retroviral
GB201706121D0 (en) * 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Stable cell lines for retroviral production
GB201715052D0 (en) 2017-09-19 2017-11-01 Oxford Genetics Ltd Vectors
FI3633040T3 (fi) 2017-12-22 2023-08-03 Oxford Biomedica Ltd Retrovirusvektori
GB201816919D0 (en) * 2018-10-17 2018-11-28 Glaxosmithkline Ip Dev Ltd Adeno-associated viral vector producer cell lines
CN110684804B (zh) * 2019-10-15 2023-04-18 上海本导基因技术有限公司 递送外源rnp的慢病毒载体及其制备方法
GB202004371D0 (en) 2020-03-26 2020-05-13 Glaxosmithkline Ip Dev Ltd CAR constructs
GB202005096D0 (en) 2020-04-07 2020-05-20 Glaxosmithkline Modified vectors for production of retrovirus
KR20220166825A (ko) * 2020-04-10 2022-12-19 사우스웨스트 리서치 인스티튜트 바이러스 벡터 생산을 위한 3차원 생물 반응기
EP4308605A1 (en) 2021-03-19 2024-01-24 GlaxoSmithKline Intellectual Property Development Limited Chimeric antigen receptors targeting claudin-3 and methods for treating cancer
CN113373266B (zh) * 2021-06-22 2022-07-01 内蒙古农业大学 一种用于检测绵羊肺腺瘤病毒的荧光rpa引物、试剂盒和检测方法
WO2024218341A1 (en) 2023-04-19 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for car-t and car-nk cells
WO2024218345A1 (en) 2023-04-21 2024-10-24 Glaxosmithkline Intellectual Property Development Limited Cytotoxicity targeting chimeras for antibody-drug conjugates and bispecific antibodies

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
WO1995003400A1 (en) 1993-07-23 1995-02-02 Johns Hopkins University School Of Medicine Recombinationally targeted cloning in yeast artificial chromosomes
ES2253754T3 (es) * 1995-06-27 2006-06-01 Bavarian Nordic A/S Celulas encapsuladas que producen particulas viricas.
WO1997030169A1 (en) 1996-02-13 1997-08-21 Fred Hutchinson Cancer Research Center 10a1 retroviral packaging cells and uses thereof
FR2751223B1 (fr) * 1996-07-19 1998-12-04 Rhone Merieux Formule de vaccin polynucleotidique felin
US6277621B1 (en) 1998-02-26 2001-08-21 Medigene, Inc. Artificial chromosome constructs containing foreign nucleic acid sequences
ATE384795T1 (de) 1998-12-31 2008-02-15 Novartis Vaccines & Diagnostic Modifizierte hiv env polypeptide
AU4364700A (en) 1999-04-22 2000-11-10 General Hospital Corporation, The Triple hybrid amplicon vector systems to generate retroviral packaging lines
US6677155B1 (en) 1999-04-22 2004-01-13 The General Hospital Corporation Triple hybrid amplicon vector systems to generate retroviral packaging lines
WO2000066758A1 (en) 1999-04-29 2000-11-09 Aarhus University Expression of heterologous genes from an ires translational cassette in retroviral vectors
AU5597200A (en) 1999-06-07 2000-12-28 Cell Genesys, Inc. Hybrid yeast-bacteria cloning system and uses thereof
WO2001027304A2 (en) 1999-10-12 2001-04-19 Institut Pasteur Lentiviral triplex dna, and vectors and recombinant cells containing lentiviral triplex dna
US20060057553A1 (en) * 2000-05-30 2006-03-16 Estuardo Aguilar-Cordova Chimeric viral vectors for gene therapy
AU2001292711A1 (en) 2000-09-18 2002-03-26 Genetic Therapy, Inc. Stress resistant retroviruses
US6586251B2 (en) * 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7214515B2 (en) 2001-01-05 2007-05-08 The General Hospital Corporation Viral delivery system for infectious transfer of large genomic DNA inserts
DE10111433A1 (de) 2001-03-09 2002-09-19 Bundesrepublik Deutschland Let Replikationskompetente molekulare Klone von porcinem endogenem Retrovirus der Klasse A und Klasse B,abgeleitet von Schweine- und humanen Zellen
WO2002097059A2 (en) 2001-05-30 2002-12-05 Chromos Molecular Systems, Inc. Chromosome-based platforms
US6835568B2 (en) * 2001-10-30 2004-12-28 Virxsys Corporation Regulated nucleic acid expression system
EP2348119B1 (en) 2002-02-01 2017-04-26 Oxford BioMedica (UK) Limited Multicistronic lentiviral vector
ATE471382T1 (de) 2002-04-10 2010-07-15 Us Gov Health & Human Serv Vac-bac-shuttlevektor-system
US7300658B2 (en) * 2002-11-25 2007-11-27 Bavarian Nordic A/S Recombinant poxvirus comprising at least two compox ATI promoters
WO2005106002A2 (en) * 2004-04-28 2005-11-10 The Trustees Of The University Of Pennsylvania Polyvalent viral vectors and a system for production thereof
US20080226677A1 (en) 2004-05-06 2008-09-18 Yasuko Mori Recombinant virus vector for gene transfer into lymphoid cells
EP1652932A1 (en) 2004-11-02 2006-05-03 GBF Gesellschaft für Biotechnologische Forschung mbH Method for the generation of virus producing cell lines and cell lines
EP1817422A2 (en) 2004-11-24 2007-08-15 Nanovector Limited Viral vectors
EP1829963A4 (en) * 2004-11-24 2009-01-28 Anaeropharma Science Inc NEW SHUTTLE VECTOR
EP2062246A4 (en) 2006-08-18 2010-09-29 Univ North Carolina VACCINES AGAINST CHIMARICAL VIRUSES
GB0702695D0 (en) * 2007-02-12 2007-03-21 Ark Therapeutics Ltd Production of vectors
CN101743306A (zh) * 2007-03-23 2010-06-16 威斯康星校友研究基金会 体细胞重编程
WO2009146150A2 (en) 2008-04-04 2009-12-03 University Of Miami Viral recombineering and uses thereof
BR112013005120A2 (pt) 2010-09-02 2021-04-20 Molmed S.P.A produção semiestável de vetores lentivirais
US9273324B2 (en) 2010-12-05 2016-03-01 Andrew S. Belmont Recombinant gene expression
WO2012170431A2 (en) 2011-06-06 2012-12-13 Bluebird Bio, Inc. Improved geneswitch systems
GB201202516D0 (en) 2012-02-13 2012-03-28 Ucl Business Plc Materials and methods relating to packaging cell lines
WO2014043131A1 (en) * 2012-09-14 2014-03-20 The Regents Of The University Of California Lentiviral vector for stem cell gene therapy of sickle cell disease
US10590433B2 (en) * 2014-03-14 2020-03-17 University Of Washington Genomic insulator elements and uses thereof
GB2538321A (en) 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Artificial chromosome for retroviral production
GB2538324A (en) 2015-05-15 2016-11-16 Glaxosmithkline Ip Dev Ltd Packaging cell line for retroviral production
KR102058113B1 (ko) * 2015-11-23 2019-12-23 주식회사 엘지화학 접착력이 개선된 리튬 이차전지용 전극 및 이의 제조방법
BR112018010635A2 (pt) 2015-11-24 2018-11-27 Glaxosmithkline Ip Dev Ltd linhagens celulares estáveis para a produção retroviral

Also Published As

Publication number Publication date
RU2018118964A3 (OSRAM) 2020-04-02
BR112018010639A2 (pt) 2019-01-22
IT201600117287A1 (it) 2018-05-21
RU2018118964A (ru) 2019-12-26
CN108291211A (zh) 2018-07-17
FR3044017A1 (fr) 2017-05-26
US20200063144A1 (en) 2020-02-27
IL259223A (en) 2018-07-31
AU2016359838A1 (en) 2018-05-24
JP2019500030A (ja) 2019-01-10
EP3380605A1 (en) 2018-10-03
AU2016359838B2 (en) 2020-08-06
US20170145427A1 (en) 2017-05-25
IL259223B (en) 2022-05-01
JP7110096B2 (ja) 2022-08-01
DE102016122317A1 (de) 2017-05-24
KR20180073624A (ko) 2018-07-02
SA518391585B1 (ar) 2020-10-26
CA3006285A1 (en) 2017-06-01
WO2017089307A1 (en) 2017-06-01
RU2749717C2 (ru) 2021-06-16
KR102067352B1 (ko) 2020-01-16
US10450574B2 (en) 2019-10-22

Similar Documents

Publication Publication Date Title
FR3044017B1 (fr) Procede de transfection transitoire pour la production retrovirale
MX2017016688A (es) Nuevas enzimas y sistemas crispr.
CL2021002739A1 (es) Proteína crispr de prevotella y francisella 1 (cpf1) aislada de acidaminococcus sp. bv3l6; proteína de fusión que la comprende; ácido nucleico; vector; métodos para alterar el genoma de una célula o una molécula de adn bicatenario in vitro que utilizan dichas proteínas (divisional de sol. 201903004)
SA518400623B1 (ar) جينات ديستروفين صغير محسنة ومجموعات إظهارها واستخدامها
EP4269577A3 (en) Nucleobase editors and uses thereof
MX2018004263A (es) Edición genómica multiplexada.
MX372651B (es) ARN SINTÉTICO PARA SU Uso EN EL TRATAMIENTO DE LA EPIDERMÓLISIS AMPOLLOSA DISTRÓFICA.
MX382822B (es) Metodos y productos para transfeccion de celulas.
BR112018010635A2 (pt) linhagens celulares estáveis para a produção retroviral
MX2017012367A (es) Producto en desarrollo de analisis de secuenciacion de alineacion y variante.
EA202091673A1 (ru) Способ амплификации нуклеиновых кислот
EP4368715A3 (en) Nucleic acid sequence analysis from single cells
EA201890012A1 (ru) Способы и композиции для рнк-направляемого лечения инфекции, вызываемой вич
EP4406585A3 (en) Nucleic acid products and methods of administration thereof
MX2022002872A (es) Nuevas sistemas y enzimas de crispr dirigidos a adn.
WO2016100955A3 (en) Compositions and methods for targeted depletion, enrichment, and partitioning of nucleic acids using crispr/cas system proteins
MX2017004285A (es) Indicador biologico.
WO2016061232A3 (en) Multiplexed shrnas and uses thereof
EP3843870C0 (en) MULTIPLE CHARGED IONIC COMPOUNDS DERIVED FROM POLYAMINES AND COMPOSITIONS BASED ON THESE COMPOUNDS AND ASSOCIATED PREPARATION METHODS
GB2564296A (en) Replicative transposon system
MX2021001578A (es) Proteina asociada a crispr novedosa y uso de la misma.
EA201070229A1 (ru) Нуклеотидные последовательности msca1, влияющие на мужскую фертильность растений, и способ их применения
BR112013018744A2 (pt) método para produzir um polipetídeo ou uma proteína recombinante
MX2022002315A (es) Anticuerpos anti-cd96 y sus metodos de uso.
WO2018067582A3 (en) Hiv-1 env fusion peptide immunogens and their use

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLFP Fee payment

Year of fee payment: 3

PLSC Publication of the preliminary search report

Effective date: 20181026

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

ST Notification of lapse

Effective date: 20250705